These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Antipsychotic-Like Efficacy of Dopamine D Sahlholm K; Gómez-Soler M; Valle-León M; López-Cano M; Taura JJ; Ciruela F; Fernández-Dueñas V Mol Neurobiol; 2018 Jun; 55(6):4952-4958. PubMed ID: 28779351 [TBL] [Abstract][Full Text] [Related]
7. Altered adenosine 2A and dopamine D2 receptor availability in the 6-hydroxydopamine-treated rats with and without levodopa-induced dyskinesia. Zhou X; Doorduin J; Elsinga PH; Dierckx RAJO; de Vries EFJ; Casteels C Neuroimage; 2017 Aug; 157():209-218. PubMed ID: 28583881 [TBL] [Abstract][Full Text] [Related]
8. Evidence for the heterotetrameric structure of the adenosine A2A-dopamine D2 receptor complex. Casadó-Anguera V; Bonaventura J; Moreno E; Navarro G; Cortés A; Ferré S; Casadó V Biochem Soc Trans; 2016 Apr; 44(2):595-600. PubMed ID: 27068975 [TBL] [Abstract][Full Text] [Related]
9. The mGlu Romero-Fernandez W; Taura JJ; Crans RAJ; Lopez-Cano M; Fores-Pons R; Narváez M; Carlsson J; Ciruela F; Fuxe K; Borroto-Escuela DO Mol Neurobiol; 2022 Oct; 59(10):5955-5969. PubMed ID: 35829830 [TBL] [Abstract][Full Text] [Related]
10. Decreased striatal adenosine A Valle-León M; Callado LF; Aso E; Cajiao-Manrique MM; Sahlholm K; López-Cano M; Soler C; Altafaj X; Watanabe M; Ferré S; Fernández-Dueñas V; Menchón JM; Ciruela F Neuropsychopharmacology; 2021 Feb; 46(3):665-672. PubMed ID: 33010795 [TBL] [Abstract][Full Text] [Related]
11. Revealing Adenosine A Fernández-Dueñas V; Gómez-Soler M; Valle-León M; Watanabe M; Ferrer I; Ciruela F Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31340557 [No Abstract] [Full Text] [Related]
12. Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. Canals M; Marcellino D; Fanelli F; Ciruela F; de Benedetti P; Goldberg SR; Neve K; Fuxe K; Agnati LF; Woods AS; Ferré S; Lluis C; Bouvier M; Franco R J Biol Chem; 2003 Nov; 278(47):46741-9. PubMed ID: 12933819 [TBL] [Abstract][Full Text] [Related]
13. Dopamine D(2) receptor-mediated modulation of adenosine A(2A) receptor agonist binding within the A(2A)R/D(2)R oligomer framework. Fernández-Dueñas V; Gómez-Soler M; Morató X; Núñez F; Das A; Kumar TS; Jaumà S; Jacobson KA; Ciruela F Neurochem Int; 2013 Jul; 63(1):42-6. PubMed ID: 23619397 [TBL] [Abstract][Full Text] [Related]
14. Novel approaches for targeting the adenosine A2A receptor. Yuan G; Gedeon NG; Jankins TC; Jones GB Expert Opin Drug Discov; 2015 Jan; 10(1):63-80. PubMed ID: 25311639 [TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of (4E)-4-(4-substitutedbenzylideneamino)-3-substituted-2,3-dihydro-2-thioxothiazole-5-carbonitrile as novel A2A receptor antagonists. Mishra CB; Sharma D; Prakash A; Kumari N; Kumar N; Luthra PM Bioorg Med Chem; 2013 Oct; 21(19):6077-83. PubMed ID: 23953686 [TBL] [Abstract][Full Text] [Related]
16. Neuroprotection by caffeine in the MPTP model of parkinson's disease and its dependence on adenosine A2A receptors. Xu K; Di Luca DG; Orrú M; Xu Y; Chen JF; Schwarzschild MA Neuroscience; 2016 May; 322():129-37. PubMed ID: 26905951 [TBL] [Abstract][Full Text] [Related]
17. Crystal structure of the adenosine A Sun B; Bachhawat P; Chu ML; Wood M; Ceska T; Sands ZA; Mercier J; Lebon F; Kobilka TS; Kobilka BK Proc Natl Acad Sci U S A; 2017 Feb; 114(8):2066-2071. PubMed ID: 28167788 [TBL] [Abstract][Full Text] [Related]
18. Adenosine A2A-D2 receptor-receptor interactions in putative heteromers in the regulation of the striato-pallidal gaba pathway: possible relevance for parkinson's disease and its treatment. Beggiato S; Antonelli T; Tomasini MC; Borelli AC; Agnati LF; Tanganelli S; Fuxe K; Ferraro L Curr Protein Pept Sci; 2014; 15(7):673-80. PubMed ID: 25175458 [TBL] [Abstract][Full Text] [Related]